Welcome to our dedicated page for MiMedx Group news (Ticker: MDXG), a resource for investors and traders seeking the latest updates and insights on MiMedx Group stock.
MiMedx Group, Inc. (NASDAQ: MDXG) is a pioneer in the field of advanced wound care and therapeutic biologics. The company specializes in developing and distributing human placental tissue allografts utilizing patent-protected processes. With a cornerstone methodology known as the PURION® Process, MiMedx ensures the production of high-quality allografts via aseptic processing techniques and terminal sterilization.
Having supplied over two million allografts through direct and consignment shipments, MiMedx is a trusted name in the healthcare sector. The company’s product range includes EpiFix for external use and AmnioFix for internal applications, alongside other innovative products such as AmnioCord, AmnioFill, EpiBurn, and EpiCord. Additionally, MiMedx markets allografts for ophthalmic surgery and dental applications through third-party licenses.
MiMedx is dedicated to transforming wound care in sectors like burn treatment, surgical procedures, sports medicine, and orthopedics. By combining its extensive portfolio with strategic initiatives, such as its recent exclusive partnership with Regenity for a 510(k) cleared, bovine-derived collagen matrix, the company aims to enhance its competitive edge and expand its market reach.
Financially, MiMedx has shown impressive growth. For 2023, the company reported net sales of $321 million, reflecting a 20% increase from the previous year. Strategically, new credit facilities have been secured to bolster financial flexibility. The company expects low double-digit net sales growth for 2024 and an adjusted EBITDA margin exceeding 20%.
Despite facing regulatory challenges, such as the FDA’s stance on the AXIOFILL product, MiMedx continues to thrive. The company is actively engaging with the FDA while maintaining the product in the market. This resilience underscores MiMedx’s commitment to compliance and innovation in providing safe and effective products.
The company’s vision is to be the leading global provider of healing solutions through relentless innovation, aiming to restore quality of life for patients. For more information, visit www.mimedx.com.
MIMEDX (NASDAQ: MDXG) has filed a patent infringement lawsuit against Surgenex in the U.S. District Court for the District of Arizona. The lawsuit alleges that several of Surgenex's placental allograft products infringe on MIMEDX's patents, seeking permanent injunctive relief and monetary damages. This is the second lawsuit against Surgenex, following earlier litigation regarding alleged corporate raiding and unfair competitive practices. MIMEDX, holding over 70 patents in the placental allograft category, plans to expand its investigation into potential patent infringements by other competitors amid the increasing number of skin substitutes entering the market.
MIMEDX Group (Nasdaq: MDXG) has announced its senior management's participation in three upcoming investor conferences in December 2024. The schedule includes:
- Mizuho Health Care Conference on Wednesday, December 11, featuring one-on-one sessions in New York, NY
- Northland Growth Conference on Thursday, December 12, with virtual one-on-one sessions
- Stifel MedTech West Coast Bus Tour on Thursday, December 12, offering one-on-one sessions in Palo Alto, CA
Interested investors can arrange meetings with MIMEDX senior management through their respective Mizuho, Northland Capital, or Stifel representatives.
MIMEDX Group (NASDAQ: MDXG) announces significant changes to Local Coverage Determinations (LCDs) for skin substitute grafts, effective February 12, 2025. The revised LCDs include key modifications: patient treatment applications increased from 4 to 8, and treatment duration extended from 12 to 16 weeks. Over 200 unproven skin substitutes will no longer be covered, while MIMEDX's EPIFIX® and EPICORD® remain on the covered products list. The company highlights that Medicare spending on skin substitutes has reached over $1 billion per month, representing a 20-fold increase over five years, which these changes aim to address.
MIMEDX Group (NASDAQ: MDXG) has announced its senior management's participation in two upcoming investor conferences in New York. The company will attend the Stifel Healthcare Conference 2024 on Monday, November 18, with a webcast scheduled for 9:45 AM ET, and the 15th Annual Craig-Hallum Alpha Select Conference on Tuesday, November 19. Investors interested in meeting with MIMEDX management at these events should contact their Stifel or Craig-Hallum representatives.
MIMEDX (MDXG) reported Q3 2024 net sales of $84 million, up 3% year-over-year, with GAAP net income of $8 million and earnings per share of $0.05. The company achieved an Adjusted EBITDA of $18 million, representing a 22% margin. Growth was driven by AMNIOEFFECT® and EPIEFFECT® products, along with the newly launched HELIOGEN® product. Gross margin remained stable at 81.8%. The company raised its 2024 net sales growth expectations to high single-digits and maintains its Adjusted EBITDA margin target above 20%.
MIMEDX Group, Inc. (Nasdaq: MDXG) has announced its plans to report operating and financial results for the third quarter ended September 30, 2024. The company will release these results after the market close on Wednesday, October 30, 2024. Following this, the MIMEDX senior management team will host a webcast and conference call to review the results, beginning at 4:30 p.m. Eastern Time on the same day.
Investors can access the conference call through various means, including a webcast link, U.S. and international investor phone numbers, and a conference ID. Additionally, a replay of the webcast will be available for approximately 30 days on the company's website following the event.
MIMEDX Group, Inc. (Nasdaq: MDXG) highlighted a New York Times article on placental allografts for treating hard-to-heal, acute, and chronic wounds. The article, titled 'Her Face Was Unrecognizable After an Explosion. A Placenta Restored It,' emphasizes the benefits of placental allografts in various wound care and surgical procedures. It also raises awareness about the opportunity for mothers to donate placentas after healthy C-section deliveries, which MIMEDX uses to produce most of its products.
The article features two patients from MIMEDX's 'Patient Story' series, showcasing their remarkable recoveries using the company's products. MIMEDX CEO Joseph H. Capper believes this article, along with a recent Nature – Scientific Reports publication, will increase awareness about the unique properties and growing clinical use of placental-derived products for treating chronic and hard-to-heal wounds.
MIMEDX Group, Inc. (Nasdaq: MDXG) announced its participation in the Symposium on Advanced Wound Care (SAWC) Fall meeting from October 2-5 in Las Vegas. The company will showcase its allograft portfolio and latest scientific and clinical evidence. Key events include:
1. A sponsored lunch symposium on the evolving wound care landscape.
2. A hands-on skills lab focusing on managing lower extremity wounds.
3. Seven accepted poster presentations covering clinical and scientific research.
MIMEDX will also have representatives at booth 511 to discuss product news and clinical information. Dr. John R. Harper, MIMEDX Chief Scientific Officer, emphasized the company's leadership in expanding understanding of placental tissue's characteristics and potential clinical benefits, particularly in inflammation and epithelialization.
Ten former employees of MiMedx Group (NASDAQ: MDXG) have filed counterclaims against the company in response to a non-compete lawsuit. The counterclaims allege that MiMedx engaged in schemes to defraud Medicare and pressured healthcare providers to use medically unnecessary products on vulnerable patients. The former employees claim they were forced to leave due to MiMedx's alleged wrongdoing, including attempts to sell products without proper FDA approval.
The counterclaims reference a December 20, 2023 FDA warning letter to MiMedx's CEO regarding the AXIOFILL product. Employees allege that MiMedx's lack of transparency about this issue led them to seek employment elsewhere. The legal action, filed by attorneys at Mintz and Fellows Labriola, portrays MiMedx's original lawsuit as an intimidation tactic against whistleblowers.
MiMedx Group (NASDAQ: MDXG) faces counterclaims from a third former employee, Jake Heikkinen, alleging the company engaged in schemes to defraud Medicare and pressure healthcare providers to use unnecessary products. Heikkinen's filing, along with two other recent complaints, accuses MiMedx of predatory sales practices and lack of transparency regarding FDA warnings about its AXIOFILL product. The counterclaims describe MiMedx's lawsuit against 10 former employees as a 'blatant intimidation tactic' and allege that the company compelled employees to sell products without proper FDA approval. These accusations follow a warning letter from the FDA to MiMedx's CEO on December 20, 2023, regarding AXIOFILL.
FAQ
What is the current stock price of MiMedx Group (MDXG)?
What is the market cap of MiMedx Group (MDXG)?
What does MiMedx Group, Inc. specialize in?
What are MiMedx's key products?
How has MiMedx performed financially in 2023?
What is the PURION® Process?
How does MiMedx handle regulatory challenges?
What new collaborations has MiMedx recently announced?
What is MiMedx's vision?
Where can I find more information about MiMedx?
What markets does MiMedx target?
Who can I contact for investor relations at MiMedx?
